Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) Net Income towards Common Stockholders (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Net Income towards Common Stockholders for 13 consecutive years, with -$572471.0 as the latest value for Q3 2025.

  • On a quarterly basis, Net Income towards Common Stockholders fell 111.44% to -$572471.0 in Q3 2025 year-over-year; TTM through Dec 2025 was -$759118.0, a 38.96% increase, with the full-year FY2025 number at -$1.3 million, down 90.72% from a year prior.
  • Net Income towards Common Stockholders was -$572471.0 for Q3 2025 at Regen BioPharma, down from -$167292.0 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $60.9 million in Q2 2022 to a low of -$67.1 million in Q1 2022.
  • A 5-year average of -$484750.8 and a median of -$144913.0 in 2023 define the central range for Net Income towards Common Stockholders.
  • Biggest YoY gain for Net Income towards Common Stockholders was 913.61% in 2022; the steepest drop was 15472.64% in 2022.
  • Regen BioPharma's Net Income towards Common Stockholders stood at $2.4 million in 2021, then plummeted by 39.42% to $1.4 million in 2022, then tumbled by 110.0% to -$144913.0 in 2023, then tumbled by 255.65% to -$515384.0 in 2024, then fell by 11.08% to -$572471.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Net Income towards Common Stockholders are -$572471.0 (Q3 2025), -$167292.0 (Q2 2025), and -$19355.0 (Q1 2025).